<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060369</url>
  </required_header>
  <id_info>
    <org_study_id>BWH CareGuide</org_study_id>
    <nct_id>NCT03060369</nct_id>
  </id_info>
  <brief_title>BWH Critical Care Study of CareGuide for Evaluation of Emerging or Established Shock</brief_title>
  <official_title>BWH Critical Care Study of CareGuide for Evaluation of Emerging or Established Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reflectance Medical, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to examine the relationship between continuously measured CareGuide™&#xD;
      muscle oxygen saturation (SmO2), tissue pH and data provided from standard monitoring&#xD;
      techniques during the care of subjects with suspected established (Cohort A) or emerging&#xD;
      (Cohort B) shock in the intensive care unit (ICU).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50 subjects meeting recruitment criteria will be enrolled with a minimum of 20&#xD;
      subjects meeting entry criteria for established shock (Cohort A).&#xD;
&#xD;
      Noninvasive near-infrared spectroscopy CareGuide™ measurements of SmO2, tissue pH and&#xD;
      hematocrit will be collected from enrollment through device removal. These data will be&#xD;
      compared to specific hemodynamic and laboratory parameters obtained as a part of routine care&#xD;
      during the CareGuide™ monitoring period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">June 2012</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peak systemic lactate</measure>
    <time_frame>Duration of monitoring (&lt; 1 week)</time_frame>
    <description>Cohort A</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak systemic lactate</measure>
    <time_frame>Duration of monitoring (&lt; 1 week)</time_frame>
    <description>Cohort B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal assessment of SmO2 and lactate</measure>
    <time_frame>Duration of monitoring (&lt; 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard hemodynamic measures stratified by shock type (cardiogenic, hypovolemic, distributive)</measure>
    <time_frame>Duration of monitoring (&lt; 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic pH</measure>
    <time_frame>Duration of monitoring (&lt; 1 week)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>Established Shock (Cohort A)</arm_group_label>
    <description>Meeting criteria i or ii, AND iii:&#xD;
i. SBP ≤ 90mm Hg for greater than 30 minutes ii. Requirement for vasopressor or ionotrope to maintain SBP &gt; 90mm Hg iii. New dysfunction of at least one organ, including altered mental status, acute renal failure (increase from baseline in serum creatinine &gt;0.3 mg/dL or by 50%), oliguria (&lt;0.5 mL/kg/h for &gt;6h) , or hepatic injury (ALT, AST, or total bilirubin &gt;2xULN)suspected by the treating physician to be caused by organ hypoperfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emerging Shock (Cohort B)</arm_group_label>
    <description>Meeting criteria i or ii, AND iii:&#xD;
i. New SBP ≤ 90mm Hg for greater than 30 minutes or recurrent shorter episodes, requiring use of or clinical anticipation of the need for fluid resuscitation or vasopressor/inotropic support to maintain SBP &gt; 90 mm Hg ii. New dysfunction of at least one organ (as defined above), including altered mental status, acute renal failure, oliguria, or hepatic injury not explained by a specific non-hemodynamic cause iii. Does not meet criteria for Established Shock</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CareGuide™ device</intervention_name>
    <description>CareGuide™ is a minimal risk, non-invasive device that uses near-infrared spectroscopy to measure skeletal muscle oxygen saturation.</description>
    <arm_group_label>Emerging Shock (Cohort B)</arm_group_label>
    <arm_group_label>Established Shock (Cohort A)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Our study population is made up of adults admitted to an ICU with established or emerging&#xD;
        shock.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who are:&#xD;
&#xD;
          1. To be admitted to the intensive care unit&#xD;
&#xD;
          2. At least 18 years of age&#xD;
&#xD;
          3. Men or Women&#xD;
&#xD;
          4. Informed consent from subject or surrogate&#xD;
&#xD;
          5. Clinical diagnosis of established (Cohort A) or emerging (Cohort B) shock, as&#xD;
             described above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with:&#xD;
&#xD;
          1. Body mass index &gt;37&#xD;
&#xD;
          2. Trauma (primary diagnosis)&#xD;
&#xD;
          3. Pregnancy&#xD;
&#xD;
          4. Non-global conditions leading to regional increased lactate production (e.g. isolated&#xD;
             thrombotic or embolic phenomena, limb, compartment syndrome)&#xD;
&#xD;
          5. Known untreated hypothyroidism&#xD;
&#xD;
          6. Known hypersensitivity to medical adhesives&#xD;
&#xD;
          7. Suspected carbon monoxide poisoning or methemoglobinemia&#xD;
&#xD;
          8. Goals of care restricting vital sign acquisition&#xD;
&#xD;
          9. Family member of investigators or study staff&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>August 1, 2013</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Stephen D. Wiviott</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Tissue Perfusion</keyword>
  <keyword>Noninvasive Monitoring</keyword>
  <keyword>Near-infrared spectroscopy</keyword>
  <keyword>CareGuide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

